Melanoma Clinical Trial
Official title:
A Phase 1/2 Open-label Rolling-arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02A
| Verified date | December 2023 |
| Source | Merck Sharp & Dohme LLC |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
Substudy 02A is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02A is to evaluate the safety and efficacy of investigational treatment arms in participants with PD-1 refractory melanoma to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of Amendment 4 (effective date: 05JAN2022), a third arm has been opened to participant enrollment, treatment with pembrolizumab and all-trans retinoic acid (ATRA). Enrollment into the first two arms, treatment with pembrolizumab + quavonlimab+ vibostolimab and treatment with pembrolizumab + quavonlimab + lenvatinib has been completed per protocol as of September 2021.
| Status | Active, not recruiting |
| Enrollment | 200 |
| Est. completion date | April 3, 2030 |
| Est. primary completion date | April 3, 2030 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 120 Years |
| Eligibility | Inclusion Criteria: - Has histologically or cytologically confirmed melanoma - Has unresectable Stage III or Stage IV melanoma, not amenable to local therapy - Has progressed on treatment with an anti-PD-1/L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies - Has imaging documenting progression per RECIST 1.1 and iRECIST after initiation of an anti-PD-1/L1 agent, or by RECIST 1.1 if progression occurred on adjuvant therapy or in the setting of rapid progression. - Has not received more than 3 lines of therapy for their advanced melanoma - Has provided a tumor biopsy - Male participants who receive lenvatinib or ATRA are abstinent from heterosexual intercourse or agree to use contraception during the intervention period and for at least 7 days after the last dose of lenvatinib or ATRA; for male participants who only receive pembrolizumab, quavonlimab, vibostolimab, or a combination, no contraception measures are needed - Female participant are not pregnant or breastfeeding and are either not a woman of child-bearing potential (WOCBP) OR use a contraceptive method that is highly effective or are abstinent from heterosexual intercourse during the intervention period and for at least 120 days after the last dose of pembrolizumab, quavonlimab, vibostolimab or 30 days after the last dose of lenvatinib or ATRA, whichever occurs last - Has adequate organ function - Has resolution of toxic effect(s) of the most recent prior therapy to Grade 1 or less (except alopecia) Exclusion Criteria: - Has a diagnosis of immunodeficiency or is receiving immunosuppressive therapy within 7 days before the first dose of study intervention - Has a known additional malignancy that is progressing or requires active treatment within the past 2 years - Has known central nervous system (CNS) metastases and/or carcinomatous meningitis - Has ocular or mucosal melanoma - Has known hypersensitivity including previous clinically significant hypersensitivity reaction to treatment with another mAb - Has an active autoimmune disease that has required systemic treatment in the past 2 years - Has an active infection requiring systemic therapy - Has known history of human immunodeficiency virus (HIV) - Has known history of hepatitis B - Has a history of (noninfectious) pneumonitis - Has a history of active tuberculosis (TB) - Has received prior systemic anticancer therapy within 4 weeks prior to randomization - Has received prior radiotherapy within 2 weeks of first dose of study intervention - Has had major surgery <3 weeks prior to first dose of study intervention - Has received a live vaccine within 30 days before the first dose of study intervention - Has participated in a study of an investigational agent within 4 weeks prior to the first dose of study intervention - Has had an allogeneic tissue/solid organ transplant - Has a pre-existing Grade =3 gastrointestinal fistula or nongastrointestinal fistula - Has radiographic evidence of encasement of invasion of major blood vessel or of intratumoral cavitation - Has clinically significant hemoptysis or tumor bleeding within 2 weeks prior to the first dose of study intervention - Has clinically significant cardiovascular disease within 12 months from first dose of study intervention |
| Country | Name | City | State |
|---|---|---|---|
| Australia | Fiona Stanley Hospital ( Site 1401) | Murdoch | Western Australia |
| Australia | Tasman Oncology Research Pty Ltd ( Site 1403) | Southport | Queensland |
| Australia | Calvary Mater Newcastle-Medical Oncology ( Site 1404) | Waratah | New South Wales |
| Australia | Melanoma Institute Australia ( Site 1402) | Wollstonecraft | New South Wales |
| France | Hopital Saint Andre ( Site 1108) | Bordeaux | Gironde |
| France | Hopital La Timone ( Site 1103) | Marseille | Bouches-du-Rhone |
| France | A.P.H. Paris, Hopital Saint Louis ( Site 1107) | Paris | |
| France | Centre Hospitalier Lyon Sud ( Site 1102) | Pierre Benite | Rhone |
| France | Institut Claudius Regaud ( Site 1105) | Toulouse cedex 9 | Haute-Garonne |
| France | Gustave Roussy ( Site 1101) | Villejuif | Ile-de-France |
| Israel | HaEmek Medical Center ( Site 1703) | Afula | |
| Israel | Rambam Health Care Campus-Oncology ( Site 1704) | Haifa | |
| Israel | Hadassah Ein Karem Jerusalem ( Site 1702) | Jerusalem | |
| Israel | Chaim Sheba Medical Center ( Site 1701) | Ramat Gan | |
| Italy | Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1399) | Milano | |
| Italy | Istituto Europeo di Oncologia ( Site 1301) | Milano | |
| Italy | Istituto Nazionale Tumori Fondazione Pascale ( Site 1302) | Napoli | |
| Italy | Istituto Oncologico Veneto IRCCS ( Site 1355) | Padova | |
| Italy | Policlinico Le Scotte - A.O. Senese ( Site 1377) | Siena | |
| Switzerland | Hôpitaux Universitaires de Genève (HUG)-Oncology ( Site 1603) | Genève | Geneve |
| Switzerland | CHUV Centre Hospitalier Universitaire Vaudois ( Site 1602) | Lausanne | Vaud |
| Switzerland | Universitaetsspital Zuerich ( Site 1601) | Zuerich Flughafen | Zurich |
| United States | University of Colorado, Anschutz Cancer Pavilion ( Site 1012) | Aurora | Colorado |
| United States | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1022) | Baltimore | Maryland |
| United States | Martha Morehouse Tower ( Site 1020) | Columbus | Ohio |
| United States | Duke Cancer Institute ( Site 1005) | Durham | North Carolina |
| United States | Inova Schar Cancer Institute ( Site 1011) | Fairfax | Virginia |
| United States | West Cancer Center - East Campus ( Site 1014) | Germantown | Tennessee |
| United States | University of Texas MD Anderson Cancer Center ( Site 1006) | Houston | Texas |
| United States | The Angeles Clinic and Research Institute ( Site 1009) | Los Angeles | California |
| United States | UCLA Hematology & Oncology ( Site 1004) | Los Angeles | California |
| United States | NYU Clinical Cancer Center ( Site 1002) | New York | New York |
| United States | University of Pennsylvania Abramson Cancer Center ( Site 1008) | Philadelphia | Pennsylvania |
| United States | Oregon Health & Science University ( Site 1013) | Portland | Oregon |
| United States | Providence Saint John's Health Center ( Site 1010) | Santa Monica | California |
| Lead Sponsor | Collaborator |
|---|---|
| Merck Sharp & Dohme LLC |
United States, Australia, France, Israel, Italy, Switzerland,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of participants who experience an adverse event (AE) | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who experience an AE will be reported. | Up to ~28 months | |
| Primary | Percentage of participants who discontinue study treatment due to an AE | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants who discontinue study treatment due to an AE will be reported. | Up to ~24 months | |
| Primary | Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) | ORR is defined as the percentage of participants in the analysis population who have a complete response (CR: disappearance of all target lesions) or partial response (PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters). Responses are according to RECIST 1.1 as assessed by blinded independent central review (BICR). RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. | Up to ~30 months | |
| Secondary | Duration of Response (DOR) per RECIST 1.1 | For participants in the analysis population who show a confirmed CR (disappearance of all target lesions) or confirmed PR (at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death due to any cause, whichever occurs first. Responses are according to RECIST 1.1 as assessed by BICR. RECIST 1.1 has been modified for this study to include a maximum of 10 target lesions and a maximum of 5 target lesions per organ. | Up to ~30 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
| Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
| Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
| Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
| Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
| Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
| Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
| Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
| Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
| Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
| Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|